Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 825M | 10.8% |
| Gross Profit | 675M | 13.8% |
| Cost of Revenue | 150M | 1% |
| Operating expense | 398M | 7.8% |
| Net Income | 241M | 29.5% |
| EBITDA | 307M | 36.9% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 7.46B | 4.3% |
| Total Liabilities | 1.43B | 5.6% |
| Total Equity | 6.03B | 4% |
| Shares Outstanding | 197M | 0.1% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 185M | 6.2% |
| Cash from investing | -13M | 55.4% |
| Cash from financing | -4.6M | 88.1% |
EPS
Financial Highlights for Biomarin Pharmaceutical in Q2 '25
Biomarin Pharmaceutical reported a revenue of 825M, which is a 10.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 675M, marking a 13.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 150M, a -1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 398M, showing a 7.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 241M, showing a 29.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 307M, showing a 36.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Biomarin Pharmaceutical with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
